<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923048</url>
  </required_header>
  <id_info>
    <org_study_id>GB261-001</org_study_id>
    <nct_id>NCT04923048</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.</brief_title>
  <official_title>A Phase Ⅰ/Ⅱ, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 study of GB261 in participants with relapsed or refractory B-cell NHL and&#xD;
      CLL. The study will consist of a dose-escalation stage(Phase 1), an expansion stage(Phase 2a)&#xD;
      and Phase 2b stage where participants will be enrolled into indication-specific cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2022</start_date>
  <completion_date type="Anticipated">June 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>During Cycle 1 (up to 21 days)</time_frame>
    <description>To determine the maximum Tolerated Dose (MTD) of GB261</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>During Cycle 1 (up to 21 days)</time_frame>
    <description>To determine the frequency and nature of Dose Limiting Toxicity (DLT) of GB261</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>From first dosing until 90 days after the last treatment</time_frame>
    <description>To determine the percentage of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To determine the Objective Response Rate (ORR) of GB261</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the Cmax of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the Tmax of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the Area Under the Curve (AUC) of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the t1/2 of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the Clearance (CL) of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>At predefined intervals up to 106 days</time_frame>
    <description>To determine the Vz of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody</measure>
    <time_frame>At predefined intervals up to 3 years</time_frame>
    <description>To determine Anti-Drug Antibody (ADA) of GB261</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To determine the progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To determine the Duration of Objective Response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Complete Response</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To determine the Duration of Objective Complete Response (DOCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To determine the Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>B Cell NHL</condition>
  <condition>CLL</condition>
  <arm_group>
    <arm_group_label>GB261</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB261</intervention_name>
    <description>Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.</description>
    <arm_group_label>GB261</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          2. CD20+ B-cell Non-Hodgkin Lymphoma or CLL who have relapsed or failed to respond to at&#xD;
             least one prior treatment regimen and for whom there is no available therapy expected&#xD;
             to improve survival&#xD;
&#xD;
          3. Adequate hepatic, h&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Key inclusion criteria：&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          3. CD20+ B-cell Non-Hodgkin Lymphoma or CLL who have relapsed or failed to respond to at&#xD;
             least one prior treatment regimen and for whom there is no available therapy expected&#xD;
             to improve survival&#xD;
&#xD;
          4. Adequate hepatic, hematologic, and renal function&#xD;
&#xD;
          5. Key exclusion criteria:&#xD;
&#xD;
          6. Burkitt lymphoma, lymphoplasmacytic lymphoma or B lymphoblastic leukemia&#xD;
&#xD;
          7. Prior treatment with systemic anti-lymphoma therapy within 4 weeks or five half-lives&#xD;
             of the drug (which is shorter) prior to the first GB261 infusion&#xD;
&#xD;
          8. History of auto-SCT or CAR-T therapy in the past 180 days and/or with any of protocol&#xD;
             specified conditions&#xD;
&#xD;
          9. Prior allo-SCT or allogeneic CAR-T&#xD;
&#xD;
         10. Prior solid organ transplantation&#xD;
&#xD;
         11. Autoimmune disease with the exceptions specified in the protocol&#xD;
&#xD;
         12. History of central nervous system(CNS) lymphoma or other CNS disease&#xD;
&#xD;
         13. Significant cardiovascular or pulmonary disease&#xD;
&#xD;
         14. Hepatitis B or C or human immunodeficiency virus (HIV)&#xD;
&#xD;
         15. Pregnant or lactating or intending to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod Ganju, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peninsula &amp; South Eastern Haematology &amp; Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Yu, MD</last_name>
    <phone>021-60751991</phone>
    <email>shawn.yu@genorbio.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B cell NHL, Phase 1/2,GB261,bispecific antibody,CD20/CD3</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

